{"classes":[{"categories":[{"measurements":[{"comment":"1-sided Upper Confidence Limit","groupId":"OG000","lowerLimit":"NA","upperLimit":"27.1","value":"10"},{"comment":"1-sided Upper Confidence Limit","groupId":"OG001","lowerLimit":"NA","upperLimit":"70.1","value":"54.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"The 6-month clinical benefit rate is defined as the percentage of participants with a response or stable disease (CR, PR, or SD) at 6 months. (CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by \\>= 50% of previously involved sites from nadir, SD: Not CR/PR or PD).","dispersionType":"80% Confidence Interval","groups":[{"description":"Gastrointestinal stromal tumor (GIST) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"GIST Single"},{"description":"Gastrointestinal stromal tumor (GIST) Cohort Patients receive 3mg/kg nivolumab IV over 30 minutes and 1mg/kg ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive 3mg/kg nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.","id":"OG001","title":"GIST Dual"}],"paramType":"NUMBER","populationDescription":"Randomized Expansion GIST Cohort Participants who received treatment Only.","reportingStatus":"POSTED","timeFrame":"At 6 months","title":"6-Month Clinical Benefit Rate [Expansion GIST Cohort Only]","type":"SECONDARY","unitOfMeasure":"percentage of participants"}